Vesicular stomatitis virus expressing a chimeric Sindbis glycoprotein containing an Fc antibody binding domain targets to Her2/neu overexpressing breast cancer cells

Virology

Volumn 316, Issue 2, 2003, Pages 337-347

  Bergman, Ira ^a,b   Whitaker Dowling, Patricia ^a   Gao, Yanhua ^a   Griffin, Judith A ^b   Watkins, Simon C ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

Breast cancer; Gene therapy; Her2 neu; Pseudotype; VSV

Indexed keywords

CHIMERIC PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; RECEPTOR; STAPHYLOCOCCUS PROTEIN A; TRASTUZUMAB; VIRUS GLYCOPROTEIN;

ANIMAL CELL; ANTIBODY TITER; ARTICLE; BREAST CANCER; CANCER THERAPY; CELL STRAIN MCF 7; CONCENTRATION (PARAMETERS); CONJUGATION; GENE OVEREXPRESSION; GENE THERAPY; HUMAN; HUMAN CELL; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN MODIFICATION; VESICULAR STOMATITIS VIRUS; VIRUS REPLICATION;

STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; VESICULAR STOMATITIS VIRUS;

EID: 0344551799     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virol.2003.07.010     Document Type: Article

References (26)

1. Atchison R.W. The role of herpesviruses in adenovirus-associated virus replication in vitro. Virology. 42:1970;155-162.
2. Balachandran S., Porosnicu M., Barber G.N. Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis. J. Virol. 75:2001;3474-3479.
3. Bergman I., Barmada M.A., Griffin J.A., Slamon D.J. Treatment of meningeal breast cancer xenografts in the rat using an anti-p185/HER2 antibody. Clin. Cancer. Res. 7:2001;2050-2056.
4. de Mattos C.A., de Mattos C.C., Rupprecht C.E. Rhabdoviruses. Knipe D., Howley P. Fundamental Virology. 2001;1245-1277 Lippincott Williams & Wilkins, Philadelphia.
5. Dubuisson J., Rice C.M. Sindbis virus attachment isolation and characterization of mutants with impaired binding to vertebrate cells . J. Virol. 67:1993;3363-3374.
6. Fernandez M., Porosnicu M., Markovic D., Barber G.N. Genetically engineered vesicular stomatitis virus in gene therapy application for treatment of malignant disease . J. Virol. 76:2002;895-904.
7. Johnson J.E., Schnell M.J., Buonocore L., Rose J.K. Specific targeting to CD4+ cells of recombinant vesicular stomatitis viruses encoding human immunodeficiency virus envelope proteins. J. Virol. 71:1997;5060-5068.
8. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685.
9. Lamb R.A., Kolakofsky D. Paramyxoviridae the viruses and their replication . Knipe D., Howley P. Fundamental Virology. 2001;689-724 Lippincott Williams & Wilkins, Philadelphia.
10. Lawson N.D., Stillman E.A., Whitt M.A., Rose J.K. Recombinant vesicular stomatitis viruses from DNA. Proc. Natl. Acad. Sci. USA. 92:1995;4477-4481.
11. Lindmark R., Thoren-Tolling K., Sjoquist J. Binding of immunoglobulins to protein A and immunoglobulin levels in mammalian sera. J. Immunol. Methods. 62:1983;1-13.
12. Morizono K., Bristol G., Xie Y.M., Kung S.K., Chen I.S. Antibody-directed targeting of retroviral vectors via cell surface antigens. J. Virol. 75:2001;8016-8020.
13. Ohno K., Sawai K., Iijima Y., Levin B., Meruelo D. Cell-specific targeting of Sindbis virus vectors displaying IgG-binding domains of protein A. Nat. Biotechnol. 15:1997;763-767.
14. Ring C.J. Cytolytic viruses as potential anti-cancer agents. J. Gen. Virol. 83:2002;491-502.
15. Rose J.K., Whitt M.A. Rhabdoviridae the viruses and their replication . Knipe D., Howley P. Fundamental Virology. 2001;1221-1244 Lippincott Williams & Wilkins, Philadelphia.
16. Russell S.J. Replicating vectors for cancer therapy a question of strategy . Semin. Cancer Biol. 5:1994;437-443.
17. Sawai K., Meruelo D. Cell-specific transfection of choriocarcinoma cells by using Sindbis virus hCG expressing chimeric vector. Biochem. Biophys. Res. Commun. 248:1998;315-323.
18. Schnell M.J., Buonocore L., Boritz E., Ghosh H.P., Chernish R., Rose J.K. Requirement for a non-specific glycoprotein cytoplasmic domain sequence to drive efficient budding of vesicular stomatitis virus. EMBO J. 17:1998;1289-1296.
19. Schnell M.J., Buonocore L., Kretzschmar E., Johnson E., Rose J.K. Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles. Proc. Natl. Acad. Sci. USA. 93:1996;11359-11365.
20. Schnell M.J., Johnson J.E., Buonocore L., Rose J.K. Construction of a novel virus that targets HIV-1-infected cells and controls HIV-1 infection. Cell. 90:1997;849-857.
21. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J., Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344:2001;783-792.
22. Stojdl D.F., Lichty B., Knowles S., Marius R., Atkins H., Sonenberg N., Bell J.C. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat. Med. 6:2000;821-825.
23. Whitaker-Dowling P., Youngner J.S., Widnell C.C., Wilcox D.K. Superinfection exclusion by vesicular stomatitis virus. Virology. 131:1983;137-143.
24. Wildner O. Oncolytic viruses as therapeutic agents. Ann. Med. 33:2001;291-304.
25. Zhang W., Mukhopadhyay S., Pletnev S.V., Baker T.S., Kuhn R.J., Rossmann M.G. Placement of the structural proteins in Sindbis virus. J. Virol. 76:2002;11645-11658.
26. Zwiebel J.A. Cancer gene and oncolytic virus therapy. Semin. Oncol. 28:2001;336-343.